These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24080309)

  • 1. Elevated and dysregulated bone morphogenic proteins in immune cells of patients with relapsing-remitting multiple sclerosis.
    Mausner-Fainberg K; Urshansky N; Regev K; Auriel E; Karni A
    J Neuroimmunol; 2013 Nov; 264(1-2):91-9. PubMed ID: 24080309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulated neurotrophin mRNA production by immune cells of patients with relapsing remitting multiple sclerosis.
    Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Farhum F; Karni A
    J Neurol Sci; 2010 Aug; 295(1-2):31-7. PubMed ID: 20541775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low and dysregulated production of follistatin in immune cells of relapsing-remitting multiple sclerosis patients.
    Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Karni A
    J Neuroimmunol; 2011 Sep; 238(1-2):96-103. PubMed ID: 21880375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.
    Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Bornstein NM; Karni A
    J Neuroimmunol; 2011 Mar; 232(1-2):171-8. PubMed ID: 21111488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
    Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
    Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated production of leukemia inhibitory factor in immune cells of relapsing remitting multiple sclerosis patients.
    Levy YA; Mausner-Fainberg K; Vaknin-Dembinsky A; Amidror T; Regev K; Karni A
    J Neuroimmunol; 2015 Jan; 278():85-9. PubMed ID: 25595256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis.
    Penn M; Mausner-Fainberg K; Golan M; Karni A
    J Neuroimmunol; 2017 Sep; 310():120-128. PubMed ID: 28778435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High and dysregulated secretion of epidermal growth factor from immune cells of patients with relapsing-remitting multiple sclerosis.
    Levy YA; Fainberg KM; Amidror T; Regev K; Auriel E; Karni A
    J Neuroimmunol; 2013 Apr; 257(1-2):82-9. PubMed ID: 23466131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity.
    Frisullo G; Angelucci F; Caggiula M; Nociti V; Iorio R; Patanella AK; Sancricca C; Mirabella M; Tonali PA; Batocchi AP
    J Neurosci Res; 2006 Oct; 84(5):1027-36. PubMed ID: 16865709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell recognition of self-antigen presenting cells by protein transfer assay reveals a high frequency of anti-myelin T cells in multiple sclerosis.
    Bahbouhi B; Pettré S; Berthelot L; Garcia A; Elong Ngono A; Degauque N; Michel L; Wiertlewski S; Lefrère F; Meyniel C; Delcroix C; Brouard S; Laplaud DA; Soulillou JP
    Brain; 2010 Jun; 133(Pt 6):1622-36. PubMed ID: 20435630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b.
    Jensen MA; Yanowitch RN; Reder AT; White DM; Arnason BG
    Mult Scler; 2010 Jan; 16(1):30-8. PubMed ID: 20007427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients.
    Giacomini E; Severa M; Rizzo F; Mechelli R; Annibali V; Ristori G; Riccieri V; Salvetti M; Coccia EM
    Eur J Immunol; 2013 Jul; 43(7):1963-72. PubMed ID: 23636665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
    Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
    J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls.
    Vanderlocht J; Hendriks JJ; Venken K; Stinissen P; Hellings N
    J Neuroimmunol; 2006 Aug; 177(1-2):189-200. PubMed ID: 16797728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy.
    Cosentino M; Zaffaroni M; Trojano M; Giorelli M; Pica C; Rasini E; Bombelli R; Ferrari M; Ghezzi A; Comi G; Livrea P; Lecchini S; Marino F
    Neuroimmunomodulation; 2012; 19(5):283-92. PubMed ID: 22472872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection.
    Azoulay D; Urshansky N; Karni A
    J Neuroimmunol; 2008 Mar; 195(1-2):186-93. PubMed ID: 18329726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.